Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02939573 · ClinicalTrials.gov registry record · Phase 2

A Randomized Multicenter Study for Isolated Skin Vasculitis

A Phase 2 study of IgA Vasculitis and Primary Cutaneous Vasculitis, sponsored by University of Pennsylvania.

Recruiting
Registry status
Phase 2
Development phase
90
Enrollment target
16
Study locations

NCT02939573 is a Phase 2 study of IgA Vasculitis and Primary Cutaneous Vasculitis that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 90 participants, below the 248-participant average among 5 other IgA Vasculitis trials with a reported enrollment target (64% lower). The trial reports 16 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02939573, a Phase 2 study of IgA Vasculitis and Primary Cutaneous Vasculitis, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
16
Study locations

Study Summary

Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin vasculitis.

Conditions Studied

IgA Vasculitis Primary Cutaneous Vasculitis Cutaneous Polyarteritis Nodosa Henoch-Schönlein Purpura

Interventions

  • DRUG Colchicine
  • DRUG Dapsone
  • DRUG Azathioprine

Study Locations (16)

New York

  • Northwell Health - Lake Success
  • Hospital for Special Surgery - New York

Pennsylvania

  • Penn State Hershey Medical Center - Hershey
  • University of Pennsylvania - Philadelphia

Ontario

  • St. Joseph's Healthcare - Hamilton
  • University of Toronto Mount Sinai Hospital - Toronto

Kansas

  • University of Kansas Medical Center - Kansas City

Massachusetts

  • Boston University School of Medicine - Boston

Minnesota

  • Mayo Clinic - Rochester

Ohio

  • Cleveland Clinic - Cleveland

Tennessee

  • Vanderbilt University - Nashville

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2017-01-01
Est. Completion 2028-12-31
Phase Phase 2

Sponsor

University of Pennsylvania

1,423 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02939573

The ClinicalTrials.gov registry entry for NCT02939573 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 248-participant average among 5 other IgA Vasculitis trials with a reported enrollment target (64% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with IgA Vasculitis appearing as the primary indexed condition, and to 3 interventions - of which Colchicine is the first listed.

NCT02939573 reports 16 study locations spanning 13 distinct geographic areas - top geographies include New York, Pennsylvania, Ontario.

Frequently Asked Questions

What is clinical trial NCT02939573 about?

NCT02939573 is a clinical study titled "A Randomized Multicenter Study for Isolated Skin Vasculitis". Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin vasculitis.

What is the current status of trial NCT02939573?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2017-01-01. Estimated completion is 2028-12-31.

What conditions does trial NCT02939573 study?

This clinical trial studies the following conditions: IgA Vasculitis, Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, Henoch-Schönlein Purpura.

What interventions are being tested in trial NCT02939573?

The interventions under investigation include: Colchicine (DRUG), Dapsone (DRUG), Azathioprine (DRUG).

Who is sponsoring clinical trial NCT02939573?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02939573 being conducted?

This trial has 16 study locations across Kansas, Massachusetts, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for IgA Vasculitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

IgA Vasculitis

All registered trials for this condition

Primary Cutaneous Vasculitis

All registered trials for this condition

Kansas

All trials with a study site in Kansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.